TCM in the Treatment of Lung Adenocarcinoma

• Status: Not yet recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henan University of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

• A confirmed diagnosis of LADC.

• Age ranges from17years to75years.

• A KPS score ≥40.

• Without radiotherapy, immunotherapy and targeted therapy.

• Without participanting in any other trial.

• With signed informed consent.

Exclusion Criteria:

• Pregnant, nursing or may become pregnant women.

• The patient has a history of allergy to any of the components of the intervention drug;

• Patients with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases.

• Unconscious or unable to communicate normally.

• Patients with poor compliance.